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Keratin 14-Null Cells as a Model to Test the Efficacy
of Gene Therapy Approaches in Epithelial Cells
Mariella D’Alessandro1, Stephanie E. Coats1, Marcel F. Jonkmann2, Irene M. Leigh3 and E. Birgitte Lane1,4
Skin fragility disorders caused by keratin mutations are incurable, and a better understanding of their etiology
is needed to find new ways to improve and treat these conditions. The best-studied skin fragility disorder is
epidermolysis bullosa simplex (EBS), an autosomal dominant condition caused by mutations in keratin 5 (K5) or
K14. To analyze disease mechanisms and develop gene therapy strategies, we have used keratinocyte cell lines
derived from EBS patients as model systems. Here, we describe two cell lines established from EBS patients with
K14-null mutations. We analyze the responses of these cells to stress assays previously shown to discriminate
between wild-type and keratin-mutant keratinocytes, to directly evaluate the efficacy of rescuing K14-null cells
by supplementation with wild-type K14 complementary DNA (cDNA). The K14-null cells show elevated levels of
stress correlating with reduced normal keratin function. By transfecting wild-type K14 into these cells, we
demonstrate ‘‘proof of principle’’ that an add-back approach can significantly rescue the normal keratinocyte
behavior profile. These K14-null cell lines provide a disease model for studying the effects of keratin ablation in
EBS patients and to test the efficacy of gene add-back and other therapy approaches in keratinocytes.
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INTRODUCTION
Gene therapy strategies for dominant monogenic disorders,
such as epidermolysis bullosa simplex (EBS), are often
designed to silence the mutant gene first and then correct
the pathological phenotype through addition of a wild-type
gene. Different approaches from chimeric RNA/DNA oligo-
nucleotides, small interfering RNAs (Richardson et al., 2002;
Hickerson et al., 2006; Leachman et al., 2008), antisense
(Kurreck, 2003), and ribozyme technologies (Samarsky
et al., 2000; Kashani-Sabet, 2002) are being developed to
switch off mutant genes. However, the consequences of
silencing major structural genes such as keratins have not
been well studied, in spite of published suggestions that total
lack of keratin 14 (K14) may be less pathogenic than the
presence of a defective dominant mutant K14 (Chan et al.,
1994; Jonkman et al., 1996b; Batta et al., 2000; Lanschuetzer
et al., 2003).
Keratinocyte cell lines with total absence of K14 provide
an ideal model to study the effect of a defective keratin
inactivation in EBS patients. EBS was the first disease in
which intermediate filament mutations were identified. It is
mainly an autosomal dominant skin disorder, caused by
mutations in either K5 or K14 (Bonifas et al., 1991; Coulombe
et al., 1991; Lane et al., 1992). These keratin filament
proteins are synthesized and assembled as co-polymers of K5/
K14 in the basal cells of stratified epithelia. They form
networks of bundled filaments that link into desmosomes and
hemidesmosomes, and provide physical resilience across the
whole epithelial sheet tissue. Mutations in either K5 or K14
compromise the whole filament network and lead to fragile
epidermal basal cells that easily rupture on physical trauma
to the epidermis, giving rise to intraepithelial blisters
(reviewed in Porter and Lane, 2003). The different degrees
of clinical severity of EBS are correlated with the position
of K5 or K14 mutations (Letai et al., 1993), with the most
severe Dowling–Meara phenotype (DM-EBS) being caused by
mutation hotspots at either ends of the central a-helical rod
domain of the affected keratin (most frequently in the arginine
codon at position 125 in K14) and the mildest EBS phenotype
(Weber–Cockayne-EBS) being mainly caused by mutations in
the linker regions of the keratin. Severely mutated DM
patients present with clustered blisters at various sites of their
bodies and have an elevated risk of developing basal cell
carcinoma (Fine et al., 2004), whereas blistering is generally
limited to the hands and feet (highest stress sites)
in the mild EBS patients. Cytoplasmic aggregates of misfolded
keratin protein are classically seen in the basal keratinocytes
of DM-EBS patients, and the presence of such aggregates
activates a cascade of stress response processes that are likely
to contribute to the disease phenotype (D’Alessandro et al.,
2002; Russell et al., 2010).
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Although most EBS mutations are genetically dominant,
rare recessive cases exist. Some of these arise from junction
protein mutations (Huber et al., 2002; Jonkman et al., 2002;
Pasmooij et al., 2004), but most are cases of homozygous or
compound heterozygous ablation of K14 expression (Chan
et al., 1994; Rugg et al., 1994; Jonkman et al., 1996b; Batta
et al., 2000; Lanschuetzer et al., 2003; Yiasemides et al.,
2008). These patients a show moderately severe phenotype
and generalized blistering. Interestingly, total absence of K5,
the co-polymerizing partner of K14, has never been observed
in any individual, suggesting that ablation of K5 is lethal in
humans. The existence of viable K14-null individuals opens
another avenue for investigating the cellular mechanisms
underlying EBS.
We previously developed a range of experimental stress
assays, including heat shock, osmotic shock, and mechanical
stretch (D’Alessandro et al., 2002; Morley et al., 2003;
Russell et al., 2004), and used them to show that EBS patient-
derived cell lines expressing dominant-negative mutant
keratins have an accelerated, augmented, and sustained
response to stress, as seen by MAPK activation in response to
osmotic shock (D’Alessandro et al., 2002). K14-null cells,
however, do not have to cope with the stress of misfolded
protein, but neither do they have a reservoir of normal K14,
so it was unclear how they might respond to stress. Here,
we describe two cell lines established from patients with
K14-null mutations. By comparing them with other EBS
patient-derived keratinocytes and with isogenic lines re-
expressing wild-type K14, we analyze the specific effect of
K14 deficiency in the cells’ response to experimental stress
and the degree to which ‘‘normal’’ cell responses can be
restored by adding back wild-type K14. The K14-null cell
lines provide a useful disease model to study the effects of
keratin inactivation. This will give important baseline
information to design knockdown and replacement thera-
peutic strategies.
RESULTS
Addition of K14 into spontaneous K14-null EBS cells
The functional impact of K14 loss was assessed in the K14-
null keratinocyte cell lines KEB-11 and KEB-13. KEB-11 was
derived from an EBS patient with generalized blistering
(Koebner EBS), caused by a homozygous KRT14 mutation
c.314delGC (p.Ala105TrpfsX3), leading to premature termi-
nation of both copies of the K14 mRNA (Rugg et al., 1994).
KEB-13 was derived from a patient with severe generalized
skin blistering (III-2 in Jonkman et al., 1996b), caused by the
mutation c.526-2A4C in the 3
0
acceptor splice site of KRT14
intron 1 (Schuilenga-Hut et al., 2002), which leads to
misreading and premature terminations p.Ile176ValfsX2 or
p.Ile176ProfsX30 in the helix 1B of the K14 protein (Jonkman
et al., 1996b). KEB-11 and KEB-13 were compared with the
control keratinocyte cell line NEB-1 and the severely mutated
KEB-7 (K14 c.374G4C and Arg125Pro) (Morley et al., 2003).
Wild-type K14 complementary DNA (cDNA) was intro-
duced into KEB-11 and KEB-13 using retroviral vectors, and
following single-cell clonal selection, the levels of K14
expression in KEB-11þK14 and KEB-13þK14, and the ratio
of K14 to endogenous co-polymerizing K5 were assessed
(Figure 1a). Two clones showing a 1:1 ratio of K14 and K5
(clone J for KEB11þK14 and clone C for KEB13þK14;
Figure 1a) were selected for further analysis.
The introduction of K14 did not significantly affect the
expression of other keratins or junctional and desmosomal
proteins, apart from plectin. K5, K17, K18, and K19 levels did
not significantly alter in KEB-11 and KEB-13 after K14
transfection (Figure 1b), nor was there any significant change
in the levels of desmoglein 2 and E-cadherin (Figure 1b).
However, plectin expression significantly increased in
KEB-13 after K14 supplementation (Figure 1b).
After the addition of wild-type K14, the morphology of
KEB-11 and KEB-13 remained unaltered (Figure 2a). K14
networks appeared well defined and fully extended to the cell
junctions in both KEB11þK14 and KEB13þK14 cell lines
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Figure 1. Immunoblotting analysis of cell extracts. (a) Immunoblotting
analysis for clone selection. The levels of keratin 14 (K14) expression in
KEB-11þK14 and KEB-13þK14 clones, and their ratio to the endogenous
K5, were assessed. Clones J of KEB-11þK14 and C of KEB-13þK14, which
have a 1:1 ratio of K14 to K5, were selected and further expanded.
(b) Immunoblotting analysis of patient-derived cell lines. Total protein extracts
from KEB-7, NEB-1, KEB-11, KEB-13, KEB-11þK14, and KEB-13þK14 were
tested for keratins K5, K14, K17, K18, and K19, and for desmoglein 2,
E-cadherin, and plectin. Apart from the lack of K14 protein in KEB-11 and
KEB-13, and a significant increase of plectin expression in KEB-13 after
K14 supplementation, all other keratins and epidermal proteins
were present as expected. Protein loading was balanced for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels.
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(Figure 2b). Although no K14 was detectable before the add-
back experiments, both KEB-11 and KEB-13 did contain
filamentous keratin networks as seen with the antibody BL18
to K5 (Figure 2b). To sustain this filament network, one or
more type I keratin must be co-polymerizing with K5 in the
place of K14, as keratins are obligate heteropolymers. On
double immunofluorescence staining, type I keratins K19 and
K17 showed the most extensive colocalization with type II K5
(Supplementary Figure S1 online). K15 was excluded as a
potential partner for K5 because of the low degree of
colocalization (data not shown).
The growth and proliferation characteristics of KEB-11 and
KEB-13 were also unaltered by the addition of K14 in either
cell line (Figure 3), both in the short term (24 hours, Figure 3a)
and in the long term (8 days, Figure 3b).
Effect of K14 expression on responses to stress assays
Migration assays. Using a battery of in vitro stress assays, we
looked for evidence of functional rescue of KEB11 and KEB13
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Figure 2. Morphology of keratin-null and keratin add-back cell lines.
(a) Phase-contrast images of KEB-11, KEB-11þK14, KEB-13, and KEB-13þK14
show no significant morphological differences in the cells before and after
transfection with keratin 14 (scale bar¼ 1mm). (b) Immunofluorescence staining of
keratin filaments in K14-null and add-back cell lines. KEB-11, KEB-13, KEB-
11þK14, and KEB-13þK14 were fixed at 2 days after plating and
double-stained with monoclonal antibody LL001 to K14 and polyclonal antiserum
BLK18 to K5. K14 is absent in KEB-11 and KEB-13 but is strongly expressed, and
colocalized with K5, in KEB-11þK14 and KEB-13þK14 (scale bar¼ 1mm).
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Figure 3. Comparison of cell proliferation rates between different cell lines.
KEB-7, NEB-1, KEB-11, KEB-13, KEB-11þK14, and KEB-13þK14 were
counted at: (a) 24 hours after plating and (b) over 8 consecutive days.
(a) In all, 8104 cells were plated onto Greiner ThinCert tissue culture filters,
fixed after 24 hours, stained with DAPI, and counted. There was no significant
difference in the proliferation of KEB-13 and KEB-13þK14, and little
difference between KEB-11 and KEB-11þK14. (b) In all, 5 104 cells were
plated into eight T25 flasks, and the cells in one flask were counted on each of
the following 8 days. There was no significant growth rate difference between
KEB-11 (brown curve) and KEB-11þK14 (red curve), nor between KEB-13
(pink curve) and KEB-13þK14 (blue curve). K14, keratin 14. KEB-11 and
KEB11+K14 are the two steepest lines, NEB-1 is intermediate, and KEB-13,
KEB-13+K14, and KEB-7 are the lower three lines.
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following K14 supplementation. To test cell migration, we
used two models: (i) a scratch wound closure assay to assess
the effects of K14 expression on epithelial sheet migration
and (ii) a modified Boyden chamber assay, in which
keratinocytes were challenged to migrate as single cells
though 8 mm pores (Figure 4).
In the scratch wound closure assay, a single scrape was
made across a confluent sheet of keratinocytes, and the
extent of regrowth to close the scratch wound was measured
after 8 hours (Figure 4a). As previously reported (Morley et al.,
2003), the reepithelialization process was significantly faster
in the EBS dominant-negative mutant keratin cell line KEB-7
(K14 R125P) than in the control NEB-1 cell line (Figure 4a).
This was interpreted as being linked to the observed
hyperactivated stress responses of KEB-7 cells, when com-
pared with the wild-type cells.
Reepithelialization was also significantly faster in the two
K14-null cells, suggesting that they too might be in a
physiological state of preactivation or stress. Reintroduction
of K14 into KEB-11 and KEB-13 slowed down their migration,
and the cells’ behavior shifted much closer to the control
speed of wound healing (Figure 4a).
The transfilter migration assay requires single cells to
migrate through a filter. The ability of the mutant cells KEB-7
to migrate through the filter was significantly lower than the
control NEB-1 cells, with only 18% of the plated KEB-7 cells
detectable on the underside of the filter after 24 hours, against
42% of the wild-type NEB-1 (Figure 4b). The K14-null cells
KEB-11 and KEB-13 were also inefficient, with only 29% and
5% of the cells, respectively, counted through the filter at
24 hours. Introduction of wild-type K14 into these cells
significantly improved their ability to migrate, with 70% of
KEB-11þK14 and 60% of KEB-13þK14 cells detectable on
the underside of the filter by 24 hours (Figure 4b). The
different rates of migration on the 24 hours time scale appear
to be independent of cell proliferation, which is similar
among all cell lines (Figure 3a).
Response to heat shock. In earlier studies, we showed that
cells with severe dominant-negative mutations in K5 or
K14 formed keratin aggregates on exposure to heat shock,
which disappeared as the cells recovered (Morley et al.,
1995). When K14-null cell lines were exposed to heat shock,
however, no alteration was observed in the keratin filaments
neither in the KEB-11 or KEB-13 lines nor in their add-back
transfectants (Supplementary Figure S2 online). Transient
heat shock at 431 for 15minutes caused keratin aggregates
formation only in the mutant K14 cell line KEB-7. This result
indicates that heat shock-induced aggregates are directly due
to a mutant protein, rather than to the general instability of
the rest of the keratin network caused by K14 deficiency.
Response to osmotic shock. Cells respond to the transient
swelling caused by hypo-osmotic shock with the activation of
the JNK (c-Jun N-terminal kinase)/SAPK (stress-activated
protein kinase) pathway. We previously showed that cells
expressing mutant keratins react to osmotic stress with faster
JNK/SAPK activation of this pathway (D’Alessandro et al.,
2002, 2004). We tested the effect of K14 supplementation on
JNK/SAPK activation in KEB-11 and KEB-13 cells before and
after supplementation of K14. In KEB-11 and KEB-13, JNK/
SAPK activation is visible at 5minutes after stress, reaches a
plateau at 20-minute recovery, and is still detectable at
2 hours after stress (Figure 5). In KEB-11þK14 and KEB-
13þK14, JNK activation is significantly lower and 18 only
detectable from 7.5minutes until 1 hour after stress, with a
pattern similar to the one shown by the wild-type NEB-1
(Figure 5).
DISCUSSION
Gene therapy approaches for dominant-negative disorders
are usually designed to silence the mutant gene first and then
correct the pathological phenotype through addition of
the wild-type gene. But it is still not clear whether the
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Figure 4. Migration assays on K14-null and K14-add-back cell lines.
(a) Scratch wound closure assay. Scratch reduction after 8 hours is
significantly slower in the wild-type NEB-1 than in KEB-7, as reported
previously (Morley et al., 2003). Addition of wild-type K14 reduces the
closure migration rate in KEB-11 and KEB-13. (b) Transfilter migration assay.
In this assay, KEB-7, KEB-11, and KEB-13 cells migrate less than the NEB-1:
18% KEB-7, 29% KEB-11, and 5% KEB-13 cross the filter compared with 42%
NEB-1. After K14 add-back, both KEB-11þK14 (70% now migrating) and
KEB-13þK14 (60% now migrating) show greatly improved transfilter
migration. K14, keratin 14.
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inactivation of a defective gene is less detrimental to the
phenotype than the defective protein itself. EBS keratinocyte
cell lines with total absence of K14 provide us with an ideal
model to study the effects of inactivation of a defective
protein in dominant-negative disorders.
The association of EBS with mutations in K5 or K14 is well
documented, but the actual mechanisms by which these mostly
missense mutations lead to cell fragility in the basal cells of the
epidermis is still not fully understood. The most severe type of
EBS, DM-EBS, is associated with aggregates of keratin in a non-
filamentous state, and there is evidence that the misfolded K14
protein generates physiological stresses in the EBS cells. If these
stresses were proven to contribute to the disease phenotype,
then new therapeutic strategies for EBS, other than direct gene
correction, could be explored (Russell et al., 2010).
K14-null cells do not have to cope with the stress of
misfolded proteins, but neither do they have a reservoir of
normal K14. There is debate as to whether patients with the
recessive form of EBS and total lack of K14 have a milder
phenotype than patients with the DM-EBS dominant-negative
form of EBS (Chan et al., 1994). Although this has been hard
to investigate systematically, a null phenotype should lend
itself to add-back gene therapy approaches.
In this study, we used different stress assays to compare
two cell lines generated from patients expressing no K14
protein before and after K14 addition. We also looked at the
response to the same stresses in a cell line expressing a severe
dominant-negative K14 mutation (KEB-7) and in a wild-type
cell line (NEB-1).
A number of findings emerged from this study. First, we
cast light on the compensatory co-assembly of K5 with an
alternative partner to K14. In vitro, type I keratins can
associate with many type II keratins (Hatzfeld et al., 1987),
but in vivo copolymerization is much more selective. In
earlier EBS studies, both K15 and K17 have been suggested as
alternative partners to K5 in the K14-null patients (Chan et al.,
1994; Rugg et al., 1994; Jonkman et al., 1996b). In the tissue
culture environment of the present study, KEB-11 and KEB-13
cells both express many type I keratins in the absence of K14,
but K19 is the most highly expressed. K19 is less differentia-
tion restricted than most keratins, and is expressed in regions
of flexible or borderline differentiation commitment (Stasiak
et al., 1989). It has been proposed to help maintaining cells in
an indeterminate state before differentiation commitment and
has been described as a potential stem cell marker in
epidermis (Lane et al., 1991; Michel et al., 1996). However,
K19 is a short, tail-less keratin that may be less able to
generate a robust keratin filament network than the longer
keratins (Lu et al., 1993; Fradette et al., 1998). This deficit
could explain why the K14-null cells are nearly as severely
affected by stress as the DM-EBS cell line KEB-7.
The addition of K14 to K14-null cells growing in
monolayers did not affect the expression of E-cadherin or
desmoglein-2 in adherens junctions and desmosomes,
respectively. Plectin expression was, however, significantly
increased in KEB-13. Plectin is a member of the plakin family
of large cytoskeleton linker proteins, located in the desmo-
somes and hemidesmosomes, and binds keratin intermediate
filaments (Bolling et al., 2010). Plectin mutations are
associated with clinical phenotypes highly related to EBS,
such as the form of EBS associated with muscular dystrophy
(McLean et al., 1996; Smith et al., 1996; Koss-Harnes et al,
2002). The observations of elevated plectin in a K14-null cell
line indicate the existence of a feedback mechanism
operating between keratins and plectin, whereby an abnorm-
ality in keratin filament composition triggers a possible
compensatory upregulation of a keratin-binding protein.
The stress assays used in this study were specifically
developed as tracking indicators of the EBS phenotype and of
its amelioration in response to treatments. In all the assays
conducted, when wild-type K14 was added back to the K14-
null lines, the behavior of the transfected cells was shifted
closer to that of wild-type cells, demonstrating a significant
rescue of the EBS phenotype. Where they could be
compared, relative reproducibility was high between these
experiments and earlier ones (D’Alessandro et al., 2002;
Russell et al., 2004; Liovic et al., 2008). The lack of aggregate
formation after heat shock in K14-null cells clarifies inter-
pretation of the heat shock-induced aggregates as directly
due to mutant protein rather than to the general instability of
the rest of the keratin network, because of the deficiency of
K14. KEB-11 and KEB-13 cells, in fact, do not make any
abnormal protein that would contribute to misfolding and
aggregate formation.
We included two different migration assays in this battery
and, interestingly, they gave nearly opposite results. In the
scratch wound assay, mutant cells migrated faster than wild-
type cells, moving as a continuous epithelial sheet to close the
scratch wound. In the transfilter migration assay, the mutant
cells, moving individually, were less efficient at migrating
through the filter pores than wild-type cells, as measured by net
cell numbers across the filter after 24hours. These two assays
measure very different cell behaviors. Normal epithelial cells
always migrate as a compact sheet, and the scratch wound
NEB-1
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Figure 5. c-Jun N-terminal kinase (JNK) phosphorylation in response to
hypo-osmotic shock. In KEB-11 and KEB-13, JNK1 (p46) and JNK2 (p54)
activation is detectable at 5minutes after cessation of the stress (weaker
in KEB-11). The response continues to rise in all the epidermolysis bullosa
simplex lines, peaking at 20minutes and remaining detectable at 2 hours after
stress. In KEB-11þK14 and KEB-13þK14, JNK1/2 activation is significantly
attenuated, being only detectable at 7.5minutes of recovery and never
reaching high levels. GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
K14, keratin 14; pJNK, phosphorylated c-Jun N-terminal kinase.
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assay therefore reflects a more normal activity. The transfilter
migration assay requires single cells to migrate through pores in
a filter in a behavior that mimics metastatic epithelial cells
rather than normal epithelial sheets. K14-null cells showed no
obvious signs of metastatic behavior, although severe EBS has
Indeed been associated with a greater incidence of skin cancer
(Fine et al., 2004). These results also emphasize the need for
careful selection of appropriate functional assays.
We have previously obtained experimental evidence for a
direct correlation between the severity of the mutation carried
by an EBS cell line and the speed of JNK activation, with more
severe mutations associated with faster and more sustained
activation (D’Alessandro et al., 2002). Here, we demonstrate
that the addition of K14 to K14-null cell lines reduces their JNK
activation levels, shifting their SAPK/JNK stress response path-
way closer to that of cells with wild-type keratin.
The assays used in this study showed that the absence of
K14 leads to a constitutive stress, as in the case of dominant
missense mutations, even though in K14 null cells there are
no visible protein aggregation consequences. However, the
level of JNK/SAPK activation is clearly lower in the K14-null
lines than in KEB-7, supporting the hypothesis that a K14-null
phenotype is less severe than a DM-RBS phenotype (Chan
et al., 1993; Jonkman et al., 1996a, b).
Curative therapy for genetic skin disorders will require
some alteration of the genetic expression profile of the
affected cells or some form of bypassing of the defect. But
whatever methods are adopted for correcting the defects in
cells and tissues (Wells, 2004), disease model culture systems
will always be required to demonstrate the effectiveness
at early stages of specific gene therapy development.
Efficient models to better understand the disease mechanisms
and discover more generic ways of therapeutically
ameliorating tissue fragility disorders are needed (Gonzalez-
Gonzalez et al., 2009; Russell et al., 2010; Wally et al.,
2010). The results presented here show that the two
K14-null cell lines KEB-11 and KEB-13 can be used as
such models for epithelial cells. By transfecting wild-type
K14 into these cells and testing them with various stress
assays, we were able to demonstrate that an add-back
approach can significantly rescue the normal keratinocyte
behavior profile.
MATERIALS AND METHODS
Cell culture
The keratinocyte-derived cell lines used in this study were NEB-1
(wild type), KEB-7 (K14, c. 374G4C) (Morley et al., 2003), KEB-11
(K14, c.314delGC), and KEB-13 (K14, c.526-2A4C). Primary
keratinocytes from the patients, obtained in accordance with the
Declaration of Helsinki protocols and with informed consent, were
immortalized using HPV16 E6^E7 and neomycin selection for NEB-
1, KEB-7, and KEB-11 (Morley et al., 2003). For KEB-13, LXSNE6E7
retrovirus was used (courtesy of Dr T Brown, Fred Hutchinson
Cancer Research Center, Seattle; Roecklein and Torok-Storb, 1995).
Experiments described in this study were carried out on mutant and
control cell lines at passage 20 after immortalization. Cells were
cultured in 75% DMEM and 25% Ham’s F12 medium, with 10%
fetal calf serum, plus additional growth factors hydrocortisone
(0.4mgml1), transferrin (5mgml1), liothyronine (2 1011 M),
adenine (1.9 104 M), insulin (5mgml1), and epidermal growth
factor (0.1 ngml1). All cell lines were fibroblast feeder cell
independent, and were cultured at 371C in 5% CO2.
Supplementation of wild-type K14 into K14-null cells
The human K14 wild-type cDNA (NM_000526) was cloned into the
LZRS-LacZ-Ires-Blasto vector, derived from the previously described
LZRS-LacZ vector (Kinsella and Nolan, 1996), using the BamHI and
XhoI restriction sites. This retroviral vector was transfected into
Phoenix amphotropic-packaging cells (Pear et al., 1993) by
calcium–phosphate/chloroquine-induced transfection to produce
viral particles (Kinsella and Nolan, 1996). KEB-11 and KEB-13 cells
were infected with the viral particles, drug selected with blasticidin
(D’Alessandro et al., 2004), and single-cell clones selected. The
levels of expression of transfected K14 in KEB11 and KEB13, and
their ratio, compared with the endogenous wild-type K5 were
assessed by immunoblotting with LL001 monoclonal antibody
against K14 and BL18 rabbit polyclonal antibody against K5 (Purkis
et al., 1990). Clones with an approximately 1:1 ratio of K14 and K5
were further selected and expanded.
Keratin expression
Monoclonal antibodies used in this study were: LL001 against K14
(Purkis et al., 1990); E3 against K17 (Guelstein et al., 1988), LP34
reacting with keratins K1, K5, K6, and K18 (Lane and Alexander,
1990), and LP2K against K19 (Bo¨ttger et al., 1995). A rabbit
polyclonal antiserum, RbaK5 (BL18), was used against K5 (Purkis
et al., 1990). Cells were grown on coverslips for 2 days, fixed with
ice-cold methanol: acetone (1:1 ratio) for 5minutes, immunostained
with different antibodies, and analyzed, as previously described
(D’Alessandro et al., 2002). Immunoblotting was carried out using
the above antibodies plus LDK18 against K18 (EBL, unpublished),
anti-Dsg2 against desmoglein 2 (a gift from late M Wheelock,
University of Toledo, Ohio), HD121 against plectin (Hieda et al.,
1992), and 36/E-Cadherin against E-cadherin (BD Transduction
Laboratories, East Rutherford, NJ).
Cell proliferation
The growth rates of all cell lines were measured by plating 5 104
cells into eight T25 flasks (Greiner Bio-One GmbH, Frickenhausen,
Germany). On each of the 8 days after plating, cells were dispersed
by trypsin treatment and counted with a Coulter counter (Beckman
Coulter, Luton, UK). To determine the cells’ growth rate on the
Greiner ThinCert tissue culture filter (see below), over a 24 hours
period, 8 104 cells were plated onto each membrane, fixed after
24 hours, stained with DAPI (Invitrogen, Carlsbad, CA) and counted.
Scratch wound assay
Simple scratch wounds were made with a yellow Gilson pipette
tip in all wells of a 24-well plate of cells previously grown to
confluence over 5 days. A total of 12 wells were fixed with
methanol: acetone (1:1 ratio) at time zero and the remaining wells
were fixed after 8 hours of continued growth. The areas of the
wounds were measured using Axiovision 3.0 software (Carl Zeiss
Vision GmbH, Oberkochen, Germany) and the reduction in wound
size was calculated (Morley et al., 2003).
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Transfilter migration assay
ThinCert tissue culture inserts (8.0 mm pore size, translucent
membrane) were used in a 6-well plate (Greiner Bio-One) to create
an upper and a lower chamber. The lower chamber was filled with
2ml of migration buffer (0.5% bovine serum albumin in culture
medium, plus 10% fetal calf serum as chemoattractant). In all,
5 105 cells were resuspended in 1ml of migration buffer and
added to the upper chamber on the top of the insert. The plate was
incubated at 371C. After 24 hours, 1ml of 4% paraformaldehyde
solution was added to the lower chamber for 15minutes to fix the
cells that had migrated through the filter. Membranes were washed
three times in phosphate-buffered saline, and cells remaining on top
of the filter were removed with a cotton bud. One ml of a 1/5,000
solution of DAPI in phosphate-buffered saline was added to the
lower chamber for 10minutes to stain the nuclei of the migrated
cells. The filter membranes were then cut away from the chamber
and mounted on a slide. Migrated cells were counted using
Axiovision 3.0 software. In all, 20 fields of view were counted per
slide and the average was used, expressed as % of total cells plated
at the start.
Heat stress assay
Heat stress assay was carried out as previously described (Morley
et al., 1995). Briefly, cells were plated onto coverslips and grown to
near confluence in 48 hours. Medium at 371C was exchanged for
fresh culture medium at 431C, and cells were maintained at 431C for
15minutes. Medium was then replaced and cells returned to normal
temperature. After 15minutes of recovery at 371C, coverslips were
removed, fixed with ice-cold methanol/acetone (1:1), and stained
with monoclonal antibody LP34 against K1, K5, K6, and K18 (Lane
and Alexander, 1990) and processed as above.
Osmotic stress assay
Cells were cultured to reach 80% confluence in 48 hours, and then
subjected to hypo-osmotic shock by immersion in 150mM urea for
5minutes at 371C. The hypo-osmotic solution of urea was replaced
with normal tissue culture medium, and cells were allowed to
recover for variable times (D’Alessandro et al., 2002). Cells were
lysed into extraction buffer (Liovic et al., 2009) at 0, 2.5, 5, 7.5, 10,
20, and 30minutes, and 1, 2, and 4 hours of recovery after osmotic
shock. Protein concentration was determined by Bradford assay
(Bio-Rad protein assay, Bio-Rad GmbH, Munich, Germany), and
5mg of total protein per sample was loaded on denaturing protein
gels (Invitrogen, Carlsbad, CA). Immunoblotting was carried out
using overnight incubation at 41C with antibodies to phospho-JNK/
SAPK (New England Biolabs, Ipswich, MA, dilution 1:1,000 in 5ml
blocking buffer). Bound primary antibodies were detected using a
secondary antibody of swine anti-rabbit Ig antiserum, conjugated to
horseradish peroxidase (diluted 1:1,000 in 5ml blocking buffer), and
visualized by electrochemiluminescence. A GAPDH-HRP antibody
(Abcam, Cambridge, MA) was used as loading control.
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